Drug intelligence / Profile preview

saporin

Development stage
Unknown
Lead developer
Advanced Targeting Systems
Modality
Recombinant Proteins and Enzymes
Administration
Intravenous, Intrathecal
01

Overview

Saporin is a Type I ribosome-inactivating protein (RIP) derived from the seeds of the soapwort plant (*Saponaria officinalis*). As an RNA N-glycosidase, saporin specifically and irreversibly removes a single adenine residue from the highly conserved sarcin/ricin loop of the 28S ribosomal RNA. This modification prevents the binding of elongation factors, effectively halting protein synthesis and triggering cell death via apoptosis. Unlike Type II RIPs such as ricin, saporin lacks a cell-binding B-chain, rendering it unable to enter cells independently and making it relatively non-toxic to cells lacking a specific internalizing mechanism. This property has led to its widespread use as a cytotoxic payload in the development of immunotoxins and antibody-drug conjugates (ADCs), where it is chemically linked or genetically fused to targeting moieties like monoclonal antibodies or peptides to selectively eliminate specific cell populations in oncology and neuroscience research.

Other names
Saporin-S6Saporin-S-6Saporin-S 6Saporin-6Saporin6Saporin 6
02

Targets

28S rRNA (28S ribosomal RNA)

Beyond the preview

Go deeper on saporin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on saporin.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call